Vir makes solid tumor T cell engager deal with Gilead
Vir Biotechnology and its CEO Marianne De Backer have notched yet another deal, this time with Gilead. Gilead will pay Vir $65 million upfront, with another $45 million in near-term milestones. Gilead's also paying a ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.